1. Home
  2. XOS vs NSPR Comparison

XOS vs NSPR Comparison

Compare XOS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xos Inc.

XOS

Xos Inc.

N/A

Current Price

$2.66

Market Cap

41.4M

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

N/A

Current Price

$0.44

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XOS
NSPR
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.4M
38.9M
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
XOS
NSPR
Price
$2.66
$0.44
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
144.5K
★ 179.2K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 59.49
N/A
EPS
N/A
★ N/A
Revenue
★ $45,992,000.00
$2,310,000.00
Revenue This Year
N/A
$9.14
Revenue Next Year
$37.30
$105.44
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.60
$0.43
52 Week High
$8.27
$2.41

Technical Indicators

Market Signals
Indicator
XOS
NSPR
Relative Strength Index (RSI) 38.90 27.28
Support Level $2.45 N/A
Resistance Level $3.07 $0.72
Average True Range (ATR) 0.22 0.06
MACD -0.06 0.00
Stochastic Oscillator 10.99 9.84

Price Performance

Historical Comparison
XOS
NSPR

About XOS Xos Inc.

Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Class 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: